NCT05183139View on ClinicalTrials.gov

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

Ixazomib capsules

DRUG

Pomalidomide

Pomalidomide capsules

DRUG

Lenalidomide

Lenalidomide capsules

DRUG

Dexamethasone

Dexamethasone tablets

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05183139 - A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter